Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCN VIVO Cannabis	C$1.32 +5.6%	C$1.32	C$0.80 ▼ C$4.06	C$256.62M	N/A	1.51 million shs	310,601 shs
ATTBF Abattis Bioceuticals		$0.00	$0.00 ▼ $0.00	N/A	N/A	11,650 shs	32,500 shs
LBTSF Almirall	$9.51	$9.51	$8.85 ▼ $10.18	N/A	N/A	200 shs	N/A

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCN VIVO Cannabis	0.00%	0.00%	0.00%	0.00%	0.00%
ATTBF Abattis Bioceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
LBTSF Almirall	0.00%	0.00%	0.00%	+4.51%	-1.76%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCN VIVO Cannabis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATTBF Abattis Bioceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LBTSF Almirall	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCN VIVO Cannabis	N/A	N/A	N/A	N/A
ATTBF Abattis Bioceuticals	N/A	N/A	N/A	N/A
LBTSF Almirall	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCN VIVO Cannabis	N/A	N/A	N/A	N/A	N/A	N/A
ATTBF Abattis Bioceuticals	N/A	N/A	N/A	N/A	N/A	N/A
LBTSF Almirall	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCN VIVO Cannabis	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ATTBF Abattis Bioceuticals	N/A	-$0.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LBTSF Almirall	N/A	-$0.07	N/A	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCN VIVO Cannabis	N/A	N/A	N/A	N/A	N/A
ATTBF Abattis Bioceuticals	N/A	N/A	N/A	N/A	N/A
LBTSF Almirall	N/A	N/A	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ABCN VIVO Cannabis	N/A
ATTBF Abattis Bioceuticals	32.45%
LBTSF Almirall	16.10%

Insider Ownership

Company	Insider Ownership
ABCN VIVO Cannabis	N/A
ATTBF Abattis Bioceuticals	N/A
LBTSF Almirall	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCN VIVO Cannabis	N/A	194.41 million	N/A	Not Optionable
ATTBF Abattis Bioceuticals	N/A	N/A	N/A	Not Optionable
LBTSF Almirall	1,904	N/A	N/A	Not Optionable

ABZA, ATTBF, ABCN, and LBTSF Headlines

Source	Headline
	Almirall to license Eloxx’s ZKN-013 for rare skin conditions pharmaceutical-technology.com - March 14 at 7:29 AM
	Ribosome specialist makes progress with Almirall partnership thepharmaletter.com - March 13 at 3:36 PM
	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases pipelinereview.com - March 13 at 10:36 AM
	Almirall: investors to focus on Lebrikizumab Pipeline, sales of which could peak at €450m thecorner.eu - February 26 at 5:24 AM
	Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases pmlive.com - February 21 at 1:13 PM
	Almirall, S.A. reports FY results msn.com - February 20 at 3:55 PM
	Almirall inks pact with Novo Nordisk to develop, commercialize NN-8828 for use in immune inflammatory dermatological diseases pharmabiz.com - February 20 at 10:43 AM
	Almirall licenses anti-IL-21 monoclonal antibody from Novo Nordisk thepharmaletter.com - February 19 at 1:21 PM
	Almirall revenue growth adds credibility to dermatology leadership claim thepharmaletter.com - February 19 at 1:21 PM
	Novo Licenses to Almirall Potential First-in-Class Antibody Candidate in Dermatology biospace.com - February 19 at 1:21 PM
	Almirall Achieves Robust Growth in Dermatology Sector, Expands Pipeline with Licensing Agreement news.europawire.eu - February 19 at 8:21 AM
	Almirall Secures Global Rights for Promising Dermatological Treatment, NN-8828, Targeting IL-21 news.europawire.eu - February 19 at 8:21 AM
	Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business finance.yahoo.com - February 19 at 8:21 AM
	Almirall licenses IL-21 antibody from Novo Nordisk pharmaceutical-technology.com - February 19 at 8:21 AM
	Almirall receives A- rating by CDP for its contributions to the fight against climate change pharmiweb.com - February 12 at 4:30 PM
	Almirall and Microsoft partner on AI-powered drug discovery in dermatology msn.com - February 5 at 7:06 AM
	Almirall, Microsoft team up on digital dermatology drive pharmaphorum.com - February 1 at 3:44 PM
	Microsoft enters three-year partnership with Almirall to advance research into medical dermatology technologyrecord.com - February 1 at 10:44 AM
	Almirall and Microsoft partner for dermatological drug development pharmaceutical-technology.com - February 1 at 10:44 AM
	Guillermo Almirall says Bray Wanderers ‘just have to work hard and push each other’ independent.ie - February 1 at 10:44 AM
	Almirall and Microsoft partner to accelerate digital transformation in medical dermatology pmlive.com - February 1 at 10:44 AM
	Almirall and Microsoft announce partnership for digital transformation to enable the development of novel treatments for skin diseases pharmiweb.com - January 31 at 1:16 PM
	Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases joplinglobe.com - December 21 at 8:50 AM
	Almirall S.A. to Participate in 42nd Annual J.P. Morgan Healthcare Conference news.europawire.eu - December 20 at 1:14 PM

New MarketBeat Followers Over Time

Company Descriptions

VIVO Cannabis

CVE:ABCN

ABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.

Abattis Bioceuticals

OTCMKTS:ATTBF

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Almirall

OTCMKTS:LBTSF

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial